TY - CHAP
T1 - Surface decoration of hemoglobin with polyethylene glycol
AU - Acharya, Seetharama A.
AU - Manjula, Belur N.
N1 - Funding Information:
The assistance of Dr M. Prabhakaran for the preparation of the PEGylated hemoglobin models is greatly appreciated. This research has been supported by a grant-in-aid from the American Heart Association Heritage Affiliate, the National Institutes of Health grants HL-58427 and HL-71064, and the US Army grant PR023085.
PY - 2006
Y1 - 2006
N2 - Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.
AB - Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.
UR - http://www.scopus.com/inward/record.url?scp=33749262762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749262762&partnerID=8YFLogxK
U2 - 10.1016/B978-012759760-7/50049-4
DO - 10.1016/B978-012759760-7/50049-4
M3 - Chapter
AN - SCOPUS:33749262762
SN - 9780127597607
SP - 460
EP - 469
BT - Blood Substitutes
PB - Elsevier Ltd.
ER -